8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Mar 30, 2026·SEC
Fortress Biotech, Inc.(FBIO)Earnings, Financials & Key Ratios
FBIO•NASDAQ
$2.95
Price updated Jul 6, 2026
AboutFortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.Show more
- Revenue$63M+9.7%
- EBITDA-$66M+38.1%
- Net Income$7M+114.8%
- EPS (Diluted)-0.07+97.5%
- Gross Margin66.92%+4.9%
- EBITDA Margin-103.63%+43.6%
- Operating Margin-111%+42.0%
- Net Margin10.77%+113.5%
- ROE22.51%
FBIO Price & Volume
Fortress Biotech, Inc. (FBIO) stock price & volume — 10-year historical chart
Loading chart...
Volatile Milestone Revenue Masks Structural Burn Risks
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Subsidiary Capital Dependency
Key Thesis Takeaways
- Fortress Biotech operates a complex hub-and-spoke model where consolidated financial performance is frequently distorted by non-operating gains and episodic milestone payments rather than consistent commercial scaling.
- While the company recently bolstered its liquidity to $255.8M in 2026Q1, the persistent erosion of shareholder equity, evidenced by retained earnings of -$623.7M, highlights the long-term risks of its high-burn incubator structure.
- Investors should remain cautious as the company's reliance on external financing and potential subsidiary impairment risks may continue to pressure long-term valuation.
Verdict Logic
the company's reliance on equity-based capital allocation and a history of deeply negative operating margins, such as the -169.9% margin recorded in 2025Q1, suggest that the current valuation of 12.38x P/B may not be supported by core operational performance.
FBIO Growth Metrics
Fortress Biotech, Inc. (FBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years53.64%
5 Years6.77%
3 Years-5.83%
TTM14.5%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM410.4%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM235.9%
Return on Capital
10 Years-81.48%
5 Years-95.41%
3 Years-107.86%
Last Year-67.32%
FBIO Recent Earnings
Fortress Biotech, Inc. (FBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$2.82+1381.8%
$0.22
Rev
$16M-1.8%
$16M
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.21-150.0%
$0.42
Rev
$16M-38.5%
$26M
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.11+125.6%
$0.43
Rev
$18M-16.1%
$21M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.46-48.4%
$0.31
Rev
$16M-21.9%
$21M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $2.82vs $0.22+1381.8% | $16Mvs $16M-1.8% |
| Q2 2026 | Mar 31, 2026 | $0.21vs $0.42-150.0% | $16Mvs $26M-38.5% |
| Q4 2025 | Nov 14, 2025 | $0.11vs $0.43+125.6% | $18Mvs $21M-16.1% |
| Q3 2025 | Aug 14, 2025 | $0.46vs $0.31-48.4% | $16Mvs $21M-21.9% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Fortress Biotech, Inc. (FBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.95 | $113.32M | -43.77 | 9.69% | 10.77% | 22.51% | 0.08% | |
| $43.85 | $549.92M | 30.03 | 83.06% | 86.97% | 30.21% | — | |
| $29.98 | $3.02B | -9.11 | -4.26% | -156.36% | -68.97% | — | |
| $35.39 | $25.45B | -82.30 | -71.57% | -3629.19% | -6.03% | — | |
| $1.44 | $70.88M | -6.00 | — | -1964.35% | -0.12% | — | |
| $2.66 | $246.51M | -4.93 | — | — | -38.76% | — |
Compare FBIO vs Peers
Fortress Biotech, Inc. (FBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FBIO SEC Filings & Documents
Fortress Biotech, Inc. (FBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when FBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
FBIO Frequently Asked Questions
Fortress Biotech, Inc. (FBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Fortress Biotech, Inc.'s revenue?
Fortress Biotech, Inc. (FBIO) reported $66.2M in revenue for fiscal year 2025.
How fast is Fortress Biotech, Inc. growing?
Fortress Biotech, Inc. (FBIO) grew revenue by 9.7% over the past year. This is steady growth.
Is FBIO profitable?
Yes, Fortress Biotech, Inc. (FBIO) is profitable, generating $127.8M in net income for fiscal year 2025 (10.8% net margin).
Dividend & Returns
Does FBIO pay dividends?
Fortress Biotech, Inc. (FBIO) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.
What is FBIO's return on equity?
Fortress Biotech, Inc. (FBIO) has a return on equity (ROE) of 22.5%. This is excellent, indicating efficient use of shareholder capital.
What is Fortress Biotech, Inc.'s free cash flow?
Fortress Biotech, Inc. (FBIO) generated $157.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.